Pfizer suspends more tanezumab trials

NEW YORK Drug maker Pfizer is suspending some clinical studies of a biotech drug for treating pain following reports of harmful side effects in patients, Pfizer said Monday.

The drug maker halted studies of the drug tanezumab in patients with chronic low back pain and painful diabetic peripheral neuropathy at the request of the Food and Drug Administration.

Pfizer said the suspension follows further consideration of reports of harmful side effects in osteoarthritis patients taking the drug. The company already had suspended the osteoarthritis study of tanezumab in June.

Login or Register to post a comment.